These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 31008047)

  • 1. Severe pulmonary toxicity from immune checkpoint inhibitor treated successfully with intravenous immunoglobulin: Case report and review of the literature.
    Petri CR; Patell R; Batalini F; Rangachari D; Hallowell RW
    Respir Med Case Rep; 2019; 27():100834. PubMed ID: 31008047
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thrombocytopenia in patients with melanoma receiving immune checkpoint inhibitor therapy.
    Shiuan E; Beckermann KE; Ozgun A; Kelly C; McKean M; McQuade J; Thompson MA; Puzanov I; Greer JP; Rapisuwon S; Postow M; Davies MA; Eroglu Z; Johnson D
    J Immunother Cancer; 2017; 5():8. PubMed ID: 28239462
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Pituitary immune-related adverse events induced by programmed cell death protein 1 inhibitors in advanced lung cancer patients: A report of 3 cases].
    Gu YC; Liu Y; Xie C; Cao BS
    Beijing Da Xue Xue Bao Yi Xue Ban; 2022 Apr; 54(2):369-375. PubMed ID: 35435206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pulmonary Toxicities Associated With the Use of Immune Checkpoint Inhibitors: An Update From the Immuno-Oncology Subgroup of the Neutropenia, Infection & Myelosuppression Study Group of the Multinational Association for Supportive Care in Cancer.
    Rapoport BL; Shannon VR; Cooksley T; Johnson DB; Anderson L; Blidner AG; Tintinger GR; Anderson R
    Front Pharmacol; 2021; 12():743582. PubMed ID: 34675810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Severe Immune-Related Pneumonitis With PD-1 Inhibitor After Progression on Previous PD-L1 Inhibitor in Small Cell Lung Cancer: A Case Report and Review of the Literature.
    Liang X; Guan Y; Zhang B; Liang J; Wang B; Li Y; Wang J
    Front Oncol; 2019; 9():1437. PubMed ID: 31921686
    [No Abstract]   [Full Text] [Related]  

  • 6. Steroid-refractory PD-(L)1 pneumonitis: incidence, clinical features, treatment, and outcomes.
    Balaji A; Hsu M; Lin CT; Feliciano J; Marrone K; Brahmer JR; Forde PM; Hann C; Zheng L; Lee V; Illei PB; Danoff SK; Suresh K; Naidoo J
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414264
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-related organizing pneumonitis in non-small cell lung cancer receiving PD-1 inhibitor treatment: A case report and literature review.
    Yin B; Xiao J; Li J; Liu X; Wang J
    J Cancer Res Ther; 2020; 16(7):1555-1559. PubMed ID: 33565499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis.
    Ando H; Suzuki K; Yanagihara T
    Biomedicines; 2021 Oct; 9(10):. PubMed ID: 34680601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
    Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
    Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Detect it so you can treat it: A case series and proposed checklist to detect neurotoxicity in checkpoint therapy.
    Bolz S; Ramakrishnan T; Fleischer M; Livingstone E; Stolte B; Thimm A; Kizina K; Ugurel S; Kleinschnitz C; Glas M; Zimmer L; Hagenacker T
    eNeurologicalSci; 2021 Mar; 22():100324. PubMed ID: 33604462
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association of immune-related pneumonitis with the efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer.
    Cui P; Huang D; Wu Z; Tao H; Zhang S; Ma J; Liu Z; Wang J; Huang Z; Chen S; Zheng X; Hu Y
    Ther Adv Med Oncol; 2020; 12():1758835920922033. PubMed ID: 32426052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pembrolizumab induced remission of recurrent and metastatic sinonasal squamous cell carcinoma after overcoming checkpoint-inhibitor pneumonitis: A case report and literature review.
    Nair DR; Trehan R
    Cancer Rep (Hoboken); 2023 Jul; 6(7):e1778. PubMed ID: 36601913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.
    Mahoney KM; Freeman GJ; McDermott DF
    Clin Ther; 2015 Apr; 37(4):764-82. PubMed ID: 25823918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of Pneumonitis and Pneumonia Associated With Immune Checkpoint Inhibitors for Solid Tumors: A Systematic Review and Meta-Analysis.
    Su Q; Zhu EC; Wu JB; Li T; Hou YL; Wang DY; Gao ZH
    Front Immunol; 2019; 10():108. PubMed ID: 30778352
    [No Abstract]   [Full Text] [Related]  

  • 15. Case report: Pneumonia with clinical symptoms precedes imaging evidence after immune checkpoint inhibitors combined with radiotherapy in lung squamous cell cancer.
    Wang Y; Wang Y; Yu J; Meng X
    Front Immunol; 2022; 13():998516. PubMed ID: 36189237
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful treatment of steroid-refractory immune checkpoint inhibitor-related pneumonitis with triple combination therapy: a case report.
    Utsumi H; Araya J; Okuda K; Watanabe J; Takekoshi D; Fujita Y; Hashimoto M; Wakui H; Minagawa S; Numata T; Hara H; Kuwano K
    Cancer Immunol Immunother; 2020 Oct; 69(10):2033-2039. PubMed ID: 32415507
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
    Khoja L; Day D; Wei-Wu Chen T; Siu LL; Hansen AR
    Ann Oncol; 2017 Oct; 28(10):2377-2385. PubMed ID: 28945858
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of Pneumonitis Rates and Severity in Patients With Lung Cancer Treated by Immunotherapy, Radiotherapy, and Immunoradiotherapy.
    Aiad M; Fresco K; Prenatt Z; Tahir A; Ramos-Feliciano K; Stoltzfus J; Harmouch F; Wilson M
    Cureus; 2022 Jun; 14(6):e25665. PubMed ID: 35677739
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Case Report: Anti-TNF Treatment Failure in a Patient With Immune Checkpoint Inhibitor-Induced Severe Colitis.
    Fang L; Liu C; Sun X; Liu Z
    Front Oncol; 2022; 12():925964. PubMed ID: 35814408
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immune-related pneumonitis caused by programmed death-1 inhibitor Pembrolizumab: a case report and literature review].
    Chen YL; Zhao J; Jia R; Wang HY; Zheng J; Bai CQ; Wang MZ; Xu JM
    Zhonghua Jie He He Hu Xi Za Zhi; 2017 Oct; 40(10):736-743. PubMed ID: 29050127
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.